World-leading experts to focus on RSV, a significant public health challenge with an estimated 64 million people of all ages impacted every year 1 17 abstracts to evaluate unmet medical need and ...
Blenrep is a monoclonal ADC comprising a humanised BCMA conjugated to the cytotoxic agent monomethyl auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; ...
Sales growth more than 5% and adjusted operating profit growth more than 10% CAGR 2021-26 [1] Sales ambition of more than £33 billion (CER) by 2031 Strategic focus to prevent and treat disease, with R ...
GSK plc (LSE/NYSE: GSK) has today announced that Wendy Becker will join the Board of the Company as a Non-Executive Director with effect from 1 October 2023. On joining the Board, Wendy will become a ...
AZUR-1 data to show clinically meaningful sustained complete responses with Jemperli (dostarlimab) in MSI-H/dMMR locally advanced rectal cancer GSK plc (LSE/NYSE: GSK) will present more than 20 ...
Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot ...
Approval expands the number of people who can be protected against shingles, now including all adults considered at increased risk by their healthcare provider Shingrix (Recombinant Zoster Vaccine - ...
GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial. This trial is a combined phase I/II ...
First prequalification for a malaria vaccine Important step for rolling out the vaccine to children living in regions with moderate to high transmission GSK plc (LSE/NYSE: GSK) announced today that ...
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion Separate settlement of qui tam complaint for $70 million Settlements agreed ...
Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials. Nearly 3.2 million people in Europe live with chronic hepatitis B (CHB ...